Luteinizing Hormone–Releasing Hormone Agonists: A Quick Reference for Prevalence Rates of Potential Adverse Effects
Authors:
- Lauren M. WalkerLWLauren M. Walker
- Susan TranSTSusan Tran
- John W. RobinsonJRJohn W. Robinson
- 1 December 2013
- journal article
- review article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 11 (4) , 375-384
Abstract
No abstract availableKeywords
This publication has 94 references indexed in Scilit:
- Intermittent Androgen Suppression for Rising PSA Level after RadiotherapyNew England Journal of Medicine, 2012
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Cognitive effects of androgen deprivation therapy in an older cohort of men with prostate cancerCritical Reviews in Oncology/Hematology, 2010
- Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 studyThe Lancet, 2010
- Management of complications of androgen deprivation therapy in the older manCritical Reviews in Oncology/Hematology, 2009
- Cognitive and mood changes in men undergoing intermittent combined androgen blockade for non‐metastatic prostate cancerPsycho-Oncology, 2008
- Metabolic changes during gonadotropin‐releasing hormone agonist therapy for prostate cancerCancer, 2008
- Parenteral oestrogen in the treatment of prostate cancer: a systematic reviewBritish Journal of Cancer, 2008
- Osteoporosis Management in Prostate Cancer Patients Treated with Androgen Deprivation TherapyJournal of General Internal Medicine, 2007
- Prospective study of depression and fatigue in men with advanced prostate cancer receiving hormone therapyPsycho-Oncology, 2007